This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug |
Toxicity |
Interaction Type |
Mechanism |
Reference |
|---|
| bazedoxifene (198481-32-2) | Gallstones | Synergistic | Imatinib is reported to increase plasma oestrogen levels by inhibiting its metabolism by the cytochrome P450 isoenzyme CYP3A4 | Can nifedipine and estrogen interaction with imatinib be responsible for gallbladder stone development?
|
| Ketoconazole (65277-42-1) | Skin rash | Synergistic | Ketoconazole is a potent inhibitor of the cytochrome P450 isoenzyme CYP3A4, which is involved in the metabolism of imatinib | Can nifedipine and estrogen interaction with imatinib be responsible for gallbladder stone development?
|
| Lansoprazole (103577-45-3) | Oedema Labial Genital | Synergistic | lansoprazole is a weak inhibitor of CYP3A4, thus levels of imatinib were increased | Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors
|
| Nifedipine (21829-25-4) | Abdominal Pain | Synergistic | imatinib may inhibit the metabolism of nifedipine, leading to an increase in its effects on lipids, leading to an increase in biliary secretion and gallstone development. | Clinical drugs that interact with St John's wort and implication in drug development
|
| Nifedipine (21829-25-4) | Nausea | Synergistic | imatinib may inhibit the metabolism of nifedipine, leading to an increase in its effects on lipids, leading to an increase in biliary secretion and gallstone development. | Clinical drugs that interact with St John's wort and implication in drug development
|
| Nifedipine (21829-25-4) | Vomiting | Synergistic | imatinib may inhibit the metabolism of nifedipine, leading to an increase in its effects on lipids, leading to an increase in biliary secretion and gallstone development. | Clinical drugs that interact with St John's wort and implication in drug development
|
| Rifampicin (13292-46-1) | Lower Serum Imatinib Levels | Antagonistic | Rifampicin is a known potent inducer of many cytochrome P450 isoenzymes, including CYP3A4, by which imatinib is metabolised | Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects
|